Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
University of Nebraska
Northwestern University
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center